103.60 +0.17 (0.16%)
SHPGY
| Trade SHPGY now with |
|
Stock Details
Last Trade:103.60 Change:+0.17 (0.16%) Prev Close:103.43 Open: 103.91 Days Range:103.34 – 104.16 52 Week Range: 79.02 - 105.53 Volume:1092806 P/E: N/AEPS:0.00
View AllRecent Alerts 02/09/12
Recent Alert on 02/09/12 at 7:08am
Shire pic (SHPGY) Tops Q4 EPS by 14c
Shire pic (SHPGY) Tops Q4 EPS by 14c
Shire pic (NASDAQ: SHPGY) reported Q4 EPS of $1.51, $0.14 better than the analyst estimate of $1.37. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.13 billion. For earnings history and earnings-related data... Read More
Recent Alert on 02/08/12 at 6:04pm
Trading Radar for 02/09: Sirius XM (SIRI), PepsiCo (PEP), Expedia (EXPE), Dunkin' Brands (DNKN), Linkedin (LNKD), Activision (ATVI) Report
Trading Radar for 02/09: Sirius XM (SIRI), PepsiCo (PEP), Expedia (EXPE), Dunkin' Brands (DNKN), Linkedin (LNKD), Activision (ATVI) Report
Recent Alert on 02/07/12 at 12:17pm
Shire plc (SHPGY) Gets FDA Approval for Adult ADHD Medication Vyvanse
Shire plc (SHPGY) Gets FDA Approval for Adult ADHD Medication Vyvanse
Recent Alert on 02/07/12 at 12:17pm
Shire plc (SHPGY) Gets FDA Approval for Adult ADHD Medication Vyvanse
Shire plc (SHPGY) Gets FDA Approval for Adult ADHD Medication Vyvanse
Recent Alert on 02/01/12 at 1:39pm
Unusual 11 Midday Movers 02/01: (KTCC) (MGAM) (COCO) (SGMO) Higher; (HVB) (JDAS) (IXYS) Lower
Unusual 11 Midday Movers 02/01: (KTCC) (MGAM) (COCO) (SGMO) Higher; (HVB) (JDAS) (IXYS) Lower
View AllRecent Press Releases
Press Release on 02/09/12 at 7:00am
Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34
Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34
Press Release on 02/07/12 at 12:37pm
Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
Press Release on 02/07/12 at 12:15pm
Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 12/12/11 at 2:44pm
Top Q3 Picks Of Orbimed Advisors, The World's Largest Healthcare Investment Firm
Top Q3 Picks Of Orbimed Advisors, The World's Largest Healthcare Investment Firm